A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

What Was Tested

In this phase 2 trial, researchers set out to test Semaglutide.

It had four arms (groups): NNC0662-0419 (experimental), NNC0662-0419 placebo (placebo comparator), Semaglutide (experimental) and Semaglutide placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 233 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female (sex assigned at birth, inclusive of all gender identities). Age 18 years or above at the time of signing the informed consent. Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

The full record lists 4 inclusion and 4 exclusion criteria; among the exclusions: known or suspected hypersensitivity to study intervention(s) or related products; history of type 1 or type 2 diabetes mellitus.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-06-09 with completion listed for 2027-06-14.

It ran at 25 sites in United States (24) and Puerto Rico (1).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Number of gastrointestinal adverse events (time frame: From week 0 to week 39).

It also tracked 2 secondary outcomes, for example Relative change in body weight and Change in body mass index (BMI).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 233 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.